Recent Job Openings – Sept 2012

Here is a listing of recent pharma/device/biotech job openings in training, for those who are interested:

Manager, Sales Training and Development, Sunovion, MA

Sales Training Manager – Oncology, EMD Serono, MA

Manager/Associate Director, Oncology Clinical Training & Development, Novartis, NJ

Manager/Associate Director, Sales Training (Oncology), Novartis, NJ

Sales Training Manager, Shionogi, NJ

Hospital & Specialty Sales Trainer, Daiichi-Sankyo, NJ

National Sales Trainer, Daiichi-Sankyo, NJ

Director, Talent Management, Daiichi-Sankyo, NJ

Senior Manager, Leadership Development, Daiichi-Sankyo, NJ

Manager, Medical Device Training and Communications, Ikaria, NJ

Sales Training Manager – Oncology, Astellas, IL

Sr. Manager, Training & Communication (Compliance), Abbott, IL

Manager of Sales Training, Vivus, CA

Manager/Sr. Manager, Learning Technologies, Roche/Genentech, CA

Note: Impactiviti has no connection to the hiring personnel in these companies. The links are posted strictly as a service. Apply directly to the companies according to directions given on their individual job postings.

_________

Impactiviti is the Pharmaceutical Connection Agency. As the eHarmony of sales/training/marketing, we help our pharma/biotech clients find optimal outsource vendors through our unique trusted referral network. Need something? Ask Steve.

Learn more about us here.

 

Read Full Post »

Impactiviti Daily 011109

TODAY’S NEWS

Delay on inhaled insulin – a case of FDA “ooops”??

Roches‘s Actemra (RA treatment) approved by FDA – The Food and Drug Administration cleared the medicine, Actemra, in adults with moderate to severe rheumatoid arthritis, the Swiss drugmaker said today in a statement released by its South San Francisco, California-based Genentech unit. The FDA delayed approval in 2008 after the drug was backed by the agency’s outside advisers…more

All that hubbub from the story about how well anti-depressants really work: this is a pretty telling paragraph from the NY Times – That story begins to take shape when you consider what the new study actually said: Antidepressants do work for very severely depressed people, as well as for those whose mild depression is chronic. However, the researchers found, the pills don’t work for people who aren’t really depressed — people with short-term, minor depression whose problems tend to get better on their own. For many of them, it’s often been observed, merely participating in a drug trial (with its accompanying conversation, education and emphasis on self-care) can be anti-depressant enough…more

RECOMMENDED

Curriculum Design. When it’s time to bring in some outside resources for designing curriculum (new hire, leadership, management development, etc.) we’ve got the suppliers you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Want to try a visually simple, on-line to-do list? Check out TeuxDeux.

JUST FOR FUN

A classic: The Saturday Night Live “Chicken of the Sea” skit.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Today’s Top Three in Pharma 022409

Merck has laid off 750 sales reps so far this year. Ouch.

Genentech to Roche: No. Again (translation: move us from “no” with “dough”…)

Endo brings Indevus into the fold.

PLUS – who is actively involved in social media in pharma? I’m assembling a growing list…here’s what we have so far on this expanding community.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »

Today’s Top Three in Pharma 011309

FDA approves sharing unapproved drug uses with doctors. “The public health may be advanced by healthcare professionals’ receipt of medical journal articles … on unapproved new uses,” the agency states. Such uses may even “constitute a medically recognized standard of care,” according to the agency.

The Medicines Company to acquire Targanta – Targanta’s lead product, oritavancin, is an innovative antibiotic with potent bactericidal (killing) activity against a broad range of gram-positive bacteria including staphylococcal strains with resistance to methicillin (MRSA) and vancomycin.

Roche to up the bid for Genentech – Genentech stock rose from around $84 to around $86 on news that Roche is indeed going ahead with its bid to acquire the company. The FT reports Roche is look at $95 a share for the 44 percent of the company that it does not yet own. The timing of the bid will before early February…

—–

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Read Full Post »

Pharma News 11_2

Barren pipelines abound – the drug drought of pharma.

Schering‘s promising clot drug continues to do well in trials.

Amgen and Roche go another round in court over anemia drugs – this round to Amgen.

Sleep drugs – wildly popular, but how effective? Related news: Sepracor‘s earnings (and a 16% cut in the sales force).

The 2007 drug company layoff tally – sobering.

Takeda‘s experimental cholesterol drug (lapaquistat) takes a hit.

Gila monster saliva diabetes drug looking good in longer-lasting version (Amylin‘s Byetta)

OK, it’s not pharma, but it’s a very cool idea for treating skin cancer – portable, inexpensive light therapy. Fascinating.

Read Full Post »